Express Scripts Said Poised to Start 30-Day Clock; Watson challenges patents on Bayer's Beyaz Print E-mail
By Staff and Wire Reports   
Friday, 10 February 2012 19:18
Below is a look at some of the headlines for companies that made news in the healthcare sector on February 10, 2012.

Express Scripts Inc. (NASDAQ:ESRX)
is poised to tell U.S. antitrust regulators it has delivered all the data requested regarding its purchase of Medco Health Solutions Inc. (NYSE:MHS), a move that would trigger a 30-day period for a decision on the deal, two people familiar with the matter said.

Express Scripts is expected to certify to the Federal Trade Commission today that it’s finished providing the necessary information for the antitrust review, said the people, who declined to be identified because the matter isn’t public. Under antitrust law, the agency is required to act on a merger request within 30 days of the certification.

The agency’s options then include clearing the deal, suing to block it or negotiating a settlement. It could also agree with the company to extend the 30-day period. The company and the agency aren’t engaged in discussions about a settlement or extension, the people said. The FTC isn’t expected to decide on the deal until the beginning of March, one of the people said.

Brian Henry, a spokesman for Express Scripts speaking on behalf of both companies, declined to comment in an e-mail.


Watson Pharmaceuticals Inc. (NYSE:WPI) said Friday it is challenging Bayer's (PINK:BAYRY) patent on the birth control pill Beyaz.

Watson said Bayer responded by filed a lawsuit accusing Watson of patent infringement. The Food and Drug Administration will not approve Watson's generic until the lawsuit is resolved or 30 months have passed, whichever happens first.

Beyaz also is used to treat premenstrual dysphoric disorder. It is a reformulation of earlier, popular birth control pills from Bayer, including Yaz, which the U.S. Food and Drug Administration has found may be associated with a higher risk of blood clots. By December, the FDA had not set a timetable for any changes in Yaz's labeling.

Watson said U.S. sales of the drug totaled $97 million in 2011.

Shares of Watson Pharmaceuticals fell 26 cents to close Friday at $57.99 but regained 15 cents after hours.

Also Friday:

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN)
today announced that Dr. Leonard Bell, Chief Executive Officer of Alexion Pharmaceuticals, will present at the Leerink Swann 2012 Global Healthcare Conference in New York City at 1:30 p.m. Eastern time on Thursday, February 16, 2012.

CardioNet, Inc. (NASDAQ:BEAT)
, a leading wireless medical technology company with a current focus on the diagnosis and monitoring of cardiac arrhythmias, today announced the acquisition of ECG Scanning & Medical Services, Inc. CardioNet acquired all of the outstanding shares of ECG Scanning for aggregate consideration of $5.8 million in cash at closing and up to an additional $0.6 million in cash upon the achievement of certain performance targets.

EasyMed Services Inc. (CNSX:EZM)(OTCBB:EMYSF)(MUN:EY6)
(the "Company" or "EasyMed") is pleased to announce that it has entered into an investor relations agreement (the "Agreement") with Bay Street Connect ("Bay Street"), an independent investor relations firm. Bay Street will work with EasyMed to increase the Company's exposure and to liaise with investors and brokers.

Exelixis, Inc. (Nasdaq:EXEL)
today announced the pricing of its underwritten public offering of 11,000,000 shares of newly issued common stock at a price to the public of $5.50 per share.

Fluidigm Corporation (NASDAQ:FLDM)
will move the timing of its conference call with investors to start at 1:30 p.m. PST (4:30 p.m. EST) on February 14, 2012.

Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH)
today announced results for the quarter and year ended December 31, 2011.

mPhase Technologies, Inc. (OTCBB: XDSL)
said today that it intends to file a patent based on its Smart Surface technology for a novel drug delivery system.

NeuroMetrix, Inc. (Nasdaq: NURO)
today said it plans to issue its 2011 fourth quarter financial results before the opening of the market on February 15, 2012.

Taro Pharmaceutical Industries Ltd. (Pink Sheets: TAROF)
today provided unaudited financial results for the quarter and full year ended December 31, 2011.

TRIMEDYNE, INC. (OTCBB: TMED) reported revenues of $6,656,000 for the fiscal year ended September 30, 2011, a 4% increase from revenues of $6,401,000 for the prior fiscal year.

VentriPoint Diagnostics Ltd. (TSX VENTURE:VPT) (PINKSHEETS:VPTDF)
is pleased to announce the installation of its upgraded VMS™ heart analysis system at Evelina Children's Hospital, which is part of Guy's and St. Thomas' NHS Foundation Trust in London, UK.

XenoPort, Inc. (Nasdaq:XNPT) announced today that it will provide access via the World Wide Web to its presentation at the Leerink Swann Global Healthcare Conference.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus